Drug Profile
HZN 003
Alternative Names: HZN-003; MEDI 4945Latest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Class Antigouts; Oxidoreductases; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gout
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Gout in USA (SC)
- 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
- 15 Jan 2018 New profile created from 9231031